T. Rowe Price Associates’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

T. Rowe Price Associates’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-100,000	Closed	-$361K	–	2957
2022 Q4	$361K	Sell	100,000 -12,576	-11%	-$82.3K	﹤0.01%	2299
2022 Q3	$997K	Sell	112,576 -15,418	-12%	-$128K	﹤0.01%	1753
2022 Q2	$986K	Sell	127,994 -31,601	-20%	-$253K	﹤0.01%	1901
2022 Q1	$1.51M	Hold	159,595	–	–	﹤0.01%	1809
2021 Q4	$1.11M	Hold	159,595	–	–	﹤0.01%	1983
2021 Q3	$1.52M	Hold	159,595	–	–	﹤0.01%	1847
2021 Q2	$1.59M	Buy	+159,595	New	+$1.78M	﹤0.01%	1842
2018 Q3	–	Sell	-84,401	Closed	-$3.62M	–	2612
2018 Q2	$3.62M	Sell	84,401 -72,177	-46%	-$3.31M	﹤0.01%	1477
2018 Q1	$10.2M	Sell	156,578 -21,226	-12%	-$1.5M	﹤0.01%	1328
2017 Q4	$13M	Buy	177,804 +35,068	+25%	+$2.9M	﹤0.01%	1293
2017 Q3	$13.1M	Buy	142,736 +76,847	+117%	+$5.89M	﹤0.01%	1292
2017 Q2	$4.36M	Buy	+65,889	New	+$8.16M	﹤0.01%	1429

Other funds holding LUMO

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates's LUMO Position: Q1 2023 in Review

T. Rowe Price Associates sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2023, closing a stake of 100,000 shares — an estimated $361K sold.

T. Rowe Price Associates first reported a position in LUMO in Q2 2017 and held it in 12 quarters. The position peaked at $13.1M in Q3 2017. 36 funds tracked by Wall St. Rank hold LUMO as of Q1 2023.

T. Rowe Price Associates reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
T. Rowe Price Associates sold 100,000 Lumos Pharma, Inc. Common Stock shares in Q1 2023, an estimated $361K.
T. Rowe Price Associates first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2017 and held it in 12 quarters.
T. Rowe Price Associates's Lumos Pharma, Inc. Common Stock position peaked at $13.1M in Q3 2017.
36 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2023.

Based on T. Rowe Price Associates's 13F filing for Q1 2023, filed 15 May 2023.